Phase 3
N=22
Weight Regain Treatment Post-Bariatric Surgery
Obesity, Overweight
Bottom Line
View on ClinicalTrials.gov: NCT04662801 ↗Enrolled (actual)
22
Serious AEs
0.0%
Results posted
Nov 2023
Primary outcome: Primary: Body Mass Index — 39.12; 40.48 kg/m2
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Behavioral Weight Loss (BWL) (Behavioral); Early Responder: BWL continued (Behavioral); Early Non-responder: BWL continued with medication added (Combination_product)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Yale University
- Primary completion
- Sep 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Body Mass Index |
39.12; 40.48 | — |
| SECONDARY Eating Disorder Psychopathology |
1.53; 1.46 | — |
| SECONDARY Food Craving |
1.65; 1.57 | — |
| SECONDARY Depressive Symptoms |
3.89; 3.67 | — |
Summary
This study will examine behavioral and pharmacologic (Naltrexone+Bupropion) treatments for weight regain after bariatric surgery.
Eligibility Criteria
Inclusion Criteria
- Be in the age range ≥18 years of age and ≤70 years of age
- Have a BMI ≥30 (or BMI ≥27 with a medical comorbidity) and ≤50 kg/m2
- Have had laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy
- Experiencing weight regain after bariatric surgery
- Be an otherwise healthy subject without uncontrolled medical problems, as determined by the study physician and medical co-investigators (physical examination, laboratory studies).
- Read, comprehend, and write English at a sufficient level to complete study-related materials.
- Provide a signed and dated written informed consent prior to study participation.
- Be available for participation in the study for up to 3 months.
Exclusion Criteria
- Has a predisposition to seizures (e.g., subject with a history or evidence of seizure disorder, febrile seizures during childhood, brain tumor, cerebrovascular disease, or significant head trauma; has a family history of idiopathic seizure disorder or is currently being treated with medications or treatment regimens that lower seizure threshold).
- Has a history of anorexia nervosa or history of bulimia nervosa.
- Is currently taking a medication that is a contraindication to NB medication (e.g., MAOI, opiates).
- Is currently using other medications for weight loss.
- Has a history of allergy or sensitivity to bupropion or naltrexone.
- Has a co-existing psychiatric condition that requires hospitalization or more intensive treatment (such as bipolar mood disorders, psychotic illnesses, or severe depression)
- Has untreated hypertension with a seated systolic blood pressure > 160 mmHg, diastolic blood pressure > 100 mmHg, or heart rate > 100 beats/minute.
- Has a history of congenital heart disease, cardiovascular disease, cardiac arrhythmias requiring medication, or a history of cerebrovascular pathology including stroke.
- Has current uncontrolled hypertension.
- Has current uncontrolled Type I or Type II diabetes mellitus.
- Has untreated hypothyroidism with a TSH > 1.5 times the upper limit of normal for the test laboratory with repeat value that also exceeds this limit.
- Has gallbladder disease.
- Has a history of severe renal, hepatic, neurological, chronic pulmonary disease, or any other unstable medical disorder.
- Has a recent history of drug or alcohol dependence (since having bariatric surgery).
- Is currently in active treatment for eating or weight loss.
- Is currently participating in another clinical study in which the subject is or will be exposed to an investigational or a non-investigational drug or device.
- Is breast-feeding or is pregnant or is not using a reliable form of birth control.
- Reports active suicidal or homicidal ideation.
Data sourced from ClinicalTrials.gov (NCT04662801). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.